AIP
ADMA icon

Ameritas Investment Partners’s ADMA Biologics ADMA Stock Holding History

Ameritas Investment Partners’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$175K Buy
20,938
+2,118
+11% +$19.3K ﹤0.01% 1478
2026
Q1 		$170K Hold
18,820
– – 0.01% 1365
2025
Q4 		$343K Sell
18,820
-549
-3% -$9.25K 0.01% 963
2025
Q3 		$284K Sell
19,369
-4,191
-18% -$71.8K 0.01% 1044
2025
Q2 		$429K Hold
23,560
– – 0.01% 903
2025
Q1 		$467K Hold
23,560
– – 0.02% 843
2024
Q4 		$404K Buy
23,560
+746
+3% +$14K 0.01% 938
2024
Q3 		$456K Buy
22,814
+750
+3% +$11.7K 0.01% 879
2024
Q2 		$247K Buy
22,064
+1,135
+5% +$9.52K 0.01% 1131
2024
Q1 		$138K Hold
20,929
– – ﹤0.01% 1532
2023
Q4 		$94.6K Hold
20,929
– – ﹤0.01% 1770
2023
Q3 		$74.9K Buy
20,929
+4,115
+24% +$15.8K ﹤0.01% 1854
2023
Q2 		$62K Hold
16,814
– – ﹤0.01% 1909
2023
Q1 		$55.7K Buy
16,814
+2,876
+21% +$9.94K ﹤0.01% 1906
2022
Q4 		$47.4K Hold
13,938
– – ﹤0.01% 2087
2022
Q3 		$33K Hold
13,938
– – ﹤0.01% 2252
2022
Q2 		$27K Buy
+13,938
New +$27.4K ﹤0.01% 2375
2021
Q2 		– Sell
-4,185
Closed -$7K – 3046
2021
Q1 		$7K Hold
4,185
– – ﹤0.01% 2940
2020
Q4 		$8K Hold
4,185
– – ﹤0.01% 2869
2020
Q3 		$10K Hold
4,185
– – ﹤0.01% 2699
2020
Q2 		$12K Hold
4,185
– – ﹤0.01% 2610
2020
Q1 		$12K Hold
4,185
– – ﹤0.01% 2429
2019
Q4 		$17K Hold
4,185
– – ﹤0.01% 2476
2019
Q3 		$19K Buy
4,185
+2,543
+155% +$10.6K ﹤0.01% 2407
2019
Q2 		$6K Hold
1,642
– – ﹤0.01% 2908
2019
Q1 		$6K Hold
1,642
– – ﹤0.01% 2819
2018
Q4 		$4K Hold
1,642
– – ﹤0.01% 2878
2018
Q3 		$10K Hold
1,642
– – ﹤0.01% 2821
2018
Q2 		$7K Buy
+1,642
New +$8.18K ﹤0.01% 2896

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Ameritas Investment Partners's ADMA Position: Q2 2026 in Review

Ameritas Investment Partners increased its ADMA Biologics (ADMA) stake by 11% in Q2 2026, buying an estimated $19.3K and bringing the position to 20,938 shares worth $175K. The position accounts for ﹤0.01% of the portfolio, ranked #1478.

Ameritas Investment Partners first reported a position in ADMA in Q2 2018 and has held it in 29 quarters since. The position peaked at $467K in Q1 2025. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Ameritas Investment Partners held 20,938 shares of ADMA Biologics worth $175K as of Q2 2026.
  • Ameritas Investment Partners bought 2,118 ADMA Biologics shares in Q2 2026, an estimated $19.3K.
  • ADMA Biologics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #1478 holding.
  • Ameritas Investment Partners first reported a position in ADMA Biologics in Q2 2018 and has held it in 29 quarters since.
  • Ameritas Investment Partners's ADMA Biologics position peaked at $467K in Q1 2025.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.